Low creatinine-cystatin C ratio correlates with reduced survival in cancer patients in meta-analysis
This meta-analysis examined the prognostic value of the creatinine-cystatin C ratio (CCR) in individuals with cancer. It pooled data from 12 observational trials, encompassing a total of 4439 patients. The primary outcome was overall survival (OS), with progression-free survival (PFS) as a secondary outcome. The comparator for a low CCR was not explicitly reported in the input data.
The main results showed a substantial correlation between a low CCR and reduced OS, with a hazard ratio (HR) of 1.71 (95% CI 1.49-1.96). For PFS, a strong correlation was also observed, with an HR of 1.51 (95% CI 1.29-1.77). Absolute event numbers for these outcomes were not reported. Safety and tolerability data were not available from the provided information.
Key limitations include the observational nature of the included studies, which precludes establishing causality. The specific types of cancer represented in the 4439 individuals were not reported, limiting generalizability. Other standard limitations, such as potential publication bias or heterogeneity, were not detailed in the input. Funding sources and author conflicts of interest were also not reported.
In practice, these findings suggest the CCR may be a promising and affordable prognostic biomarker for cancer patients. However, clinicians should interpret this as a correlation observed in aggregated retrospective data. Its utility for guiding specific clinical decisions in individual patients or cancer subtypes remains uncertain and requires prospective validation.